News

MARCH 2021

ANODYNECANN IS ENROLLING ELIGIBLE INTERESTED PATIENTS INTO CANNABINOID MEDICINE OBSERVATIONAL STUDY

We are excited to announce that AnodyneCann in collaboration with Applied Cannabis Research, is now a participating site to enrol eligible patients to take part in the Cannabinoid Medicine Observational Study (CMOS).

The CMOS is now recruiting 20,000 participants to be involved in a large-scale observational study of prescribed medical cannabis use in the Australian community.  The study duration is from 2020 to 2025.

Brief summary about the CMOS:

  • Study Name: Cannabinoid Medicine Observational Study (CMOS)
  • Study Type: Observational
  • Objective: Collect data about safety and efficacy of medicinal cannabis products in treatment of refractory indications, as well as data on effective dosage and effects of medicinal cannabis treatment on concomitant medication use.
  • Indications Assessed: The CMOS study will encompass a range of refractory conditions, including but not limited to: chronic pain conditions, neurological disorders, cancer pain and symptom management, psychiatric disorders, sleep disorders, palliative care, inflammatory conditions, gastrointestinal disorders, movement disorders and respiratory conditions.
  • Enrolment: Contact us at 1300 114 838
  • Eligibility Criteria: Deemed suitable for medicinal cannabis treatment upon assessment by our registered doctor  & Willing and able to provide informed consent

We welcome any patient interested to find out more about the CMOS contact our clinic manager at 1300 114 838

Welcome to Telehealth Medicinal Cannabis Clinic

* By clicking the above button you confirm you are 18 years old or older and agree to the AnodyneCann “Terms of Use